| NCT ID | NCT06064461 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vitaccess Ltd |
| Condition | Myasthenia Gravis |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2024-07-31 |
| Primary Completion | 2034-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2024-07-31 with a primary completion date of 2034-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL). The duration of the registry is 10 years from launch, and approximately 600 patients will be recruited in the US and Europe with no defined upper limit. The registry will link relevant patient- and healthcare professional (HCP)-reported data with clinical data from medical records. Patients will be recruited at clinical sites in all participating countries. In the US only, patients can additionally be recruited via community neurologists or direct-to-patient recruitment.
Eligibility Criteria
Inclusion Criteria: * Adult (age ≥18 years) with a clinically-confirmed diagnosis of myasthenia gravis (MG). * Resident in one of the scope countries. * Access to a smartphone/tablet/computer/laptop * Willing and able to provide informed consent in their local language to take part in the study. Exclusion Criteria: * Participation in a clinical trial at the time of study enrolment.
Contact & Investigator
Mark JW Larkin, PhD
PRINCIPAL INVESTIGATOR
Vitaccess Ltd
Frequently Asked Questions
Who can join the NCT06064461 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myasthenia Gravis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06064461 currently recruiting?
Yes, NCT06064461 is actively recruiting participants. Contact the research team at mark.larkin@vitaccess.com for enrollment information.
Where is the NCT06064461 trial being conducted?
This trial is being conducted at Orange, United States, O'Fallon, United States, Lexington, United States, Lumberton, United States and 4 additional locations.
Who is sponsoring the NCT06064461 clinical trial?
NCT06064461 is sponsored by Vitaccess Ltd. The principal investigator is Mark JW Larkin, PhD at Vitaccess Ltd. The trial plans to enroll 600 participants.